Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Short term Debt (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Short term Debt for 16 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Short term Debt rose 35.67% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Sep 2025, up 35.67%, and an annual FY2024 reading of $1.1 million, up 0.99% over the prior year.
  • Short term Debt was $1.4 million for Q3 2025 at China Pharma Holdings, roughly flat from $1.4 million in the prior quarter.
  • Across five years, Short term Debt topped out at $4.3 million in Q3 2021 and bottomed at $1.0 million in Q3 2023.
  • Average Short term Debt over 5 years is $2.2 million, with a median of $2.0 million recorded in 2021.
  • The sharpest move saw Short term Debt soared 137.13% in 2021, then crashed 66.73% in 2023.
  • Year by year, Short term Debt stood at $4.3 million in 2021, then plummeted by 43.61% to $2.4 million in 2022, then tumbled by 53.55% to $1.1 million in 2023, then rose by 0.99% to $1.1 million in 2024, then grew by 23.44% to $1.4 million in 2025.
  • Business Quant data shows Short term Debt for CPHI at $1.4 million in Q3 2025, $1.4 million in Q2 2025, and $1.2 million in Q1 2025.